Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Patient-Generated Health Data Collection During Chemoradiotherapy for Lung Cancer: A Pilot Study

NCT ID: NCT06342284Sponsor: The New York Proton CenterLast updated: 2026-04-13

Summary

This is an observational study involving the collection of patient-generated health data using an Apple Watch, a home pulse oximeter, and a smartphone during a course of proton beam radiotherapy for lung cancer. The study period over which this information is collected will range from the day of study enrollment until two weeks after radiotherapy completion. Subjects will complete a short satisfaction survey at the end of the study period. Other information that is collected as part of routine care for this patient population will be extracted from subjects' medical records during the study period and afterwards.

Detailed description

This is an observational study involving the collection of patient-generated health data using an Apple Watch, a home pulse oximeter, and a smartphone during a course of proton beam radiotherapy for lung cancer. The study period over which this information is collected will range from the day of study enrollment until two weeks after radiotherapy completion. Subjects will complete a short satisfaction survey at the end of the study period. Other information that is collected as part of routine care for this patient population will be extracted from subjects' medical records during the study period and afterwards. Primary Objective • To demonstrate the feasibility of patient-generated health data collection during thoracic proton beam radiotherapy for lung cancer. Secondary Objective • To demonstrate the face validity of physical activity and vital sign data collected during proton beam radiotherapy for lung cancer. Exploratory Objective • To explore associations between radiotherapy treatment parameters, wearable device data, patient-reported outcomes, adverse events, and long-term clinical outcomes.

Arms & interventions

  • RadiationProton Beam Radiation with or without concurrent chemotherapy

    Curative-intent fractionated proton beam thoracic radiotherapy, with or without concurrent chemotherapy

Outcome measures

Primary

  • Demonstrate the feasibility of patient-generated health data collection during thoracic proton beam radiotherapy for lung cancer, based on the quantity of data collected from the day of radiotherapy initiation to the day of radiotherapy completion.

    Feasibility assessed based on the quantity of data collected from day of radiotherapy initiation to day of radiotherapy completion. The feasibility of physical activity data collection will be assessed based on usage information provided by the Apple Watch. Descriptive statistics to be used to report the distribution of average use times in the study cohort and the proportion of days subjects wear the Apple Watch for at least 8 hours. The feasibility of daily home pulse oximeter data collection reported using frequencies and percentages. The feasibility of weekly electronic PRO collection reported using frequencies and percentages.

    Time frame: 4-5 Weeks

Secondary

  • Demonstrate the face validity of physical activity and vital sign data collected in this trial by reviewing the distribution of values obtained for each measure quantitatively using descriptive statistics.

    Time frame: 4-5 Weeks

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Plan for fractionated (≥15 treatments) proton beam thoracic radiotherapy with curative intent for lung cancer * Non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) histology is permitted. * Concurrent chemotherapy is permitted but not required.. * Previous thoracic radiotherapy is allowed. * Ability to complete study surveys in English or Spanish * Age \>/= 18 * Concurrent enrollment on other trials is permitted * Patients who already use wearable devices and/or smartphones that monitor physical activity are eligible for this trial, provided they agree to utilize the devices provided by the study team during the study period * All patients must sign study-specific informed consent prior to study entry Exclusion Criteria: * Ongoing treatment for another cancer that is expected to affect the toxicity profile of thoracic radiotherapy * Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic

Study locations (1)

New York Proton Center

New York, New York, 10035

Recruiting
Ryan Holder, BS · Contact
646-968-9055rholder@nyproton.com
Thomas Mistretta, MS · Contact
646-568-5675tmistretta@nyproton.com
Nitin Ohri, MD · Principal Investigator
Charles Simone, MD · Sub Investigator
Annemarie Shepherd, MD · Sub Investigator
Stanislav Lazarev, MD · Sub Investigator
Alexandra Hanlon, PhD · Sub Investigator
Patient-Generated Health Data Collection During Chemoradiotherapy for Lung Cancer | Cancerify